MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer

KM Fong1,2, Y Kida1, PV Zimmerman2 and PJ Smith1,*

1Queensland Cancer Fund Research Unit, Department of Pathology, University of Queensland Medical School, Herston, Queensland, Australia 4006; 2Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia 4032.

Summary Some studies have suggested that the S allele of the MYCL oncogene, which results from an intragenic EcoRI restriction fragment length polymorphism (RFLP), may be associated with cancer susceptibility. In addition, this allele has also been linked to metastases and adverse survival in certain cancers, although studies of lung cancer patients from different populations have yielded controversial results. We studied 108 cases of surgical resected non-small-cell lung cancer (NSCLC) and found no evidence that MYCL genotypes were associated with tumor progression or a worse prognosis. However, the presence of loss of heterozygosity (LOH) at this chromosome 1p32 locus correlated significantly with regional lymph node involvement, as well as advanced TNM stage. These data indicate the existence of a chromosome 1p candidate tumour-suppressor gene(s), possibly in linkage disequilibrium with the EcoRI RFLP in specific populations, which appears to play a role in determining tumour progression in NSCLC. Refined mapping of the critical region of loss should help attempts to identify and clone the candidate gene.

Keywords: MYCL; genotype; loss of heterozygosity; tumour progression; lung cancer

In many western countries, including Australia, lung cancer is the commonest malignancy in males and the largest cause of cancer deaths. While conventional management has not dramatically changed lung cancer mortality rates, molecular developments have expanded our understanding of the mechanisms leading to lung tumorigenesis, leading to efforts to use these discoveries to optimise the treatment of lung cancer.

A potential molecular marker associated with cancer susceptibility, as well as metastases and adverse survival, is the MYCL oncogene. This gene contains an EcoRI restriction fragment length polymorphism (RFLP), which allows genotyping into either L or S alleles.

In terms of cancer susceptibility, the S allele of MYCL was more common in patients with non-Hodgkin's lymphoma (Crossen et al., 1994), and male patients with bone and soft-tissue sarcomas (Kato et al., 1990). In addition, the SS genotype was more frequent in colorectal cancer patients than in young blood donor controls (Young et al., 1994). However, the cancer-susceptibility model is controversial, as the SS genotype appears to protect against hepatocellular cancer (Taylor et al., 1993), and the S allele was not increased in patients with lung cancer (Tamai et al., 1990; Weston et al., 1992, 1994), breast cancer (Champene et al., 1992) or lymphoma/leukaemia (Chenexiv-Trench et al., 1989).

As regards tumour progression, Kawashima et al. (1988, 1992), in an initial study followed by a larger study involving 252 Japanese lung cancer patients, showed that the S allele predisposed to metastases and adverse prognosis. Conversely, this association has not been found in Caucasian (Norwegian and North American) lung cancer populations (Tamai et al., 1990; Tefre et al., 1990; Weston et al., 1992, 1994). While the conflicting results may have been owing to racial/ethnic differences, there were also significant methodological variations between the studies, such as case stratification, including heterogeneity in the subtypes of lung cancer, disease stage and treatment modalities; all factors which are known to affect tumour progression and outcome.

To address some of these possible confounders, we investigated the relationship of MYCL genotypes to tumour stage, nodal metastases and survival in a well-defined, homogeneous lung cancer subset; histologically diagnosed NSCLC patients who had curative surgery as their primary treatment and who had comprehensive post-surgical staging and follow-up.

Materials and methods

DNA was obtained from 108 cases of post-surgically staged, resected NSCLC and normal lung tissue from patients at The Prince Charles Hospital, Brisbane, Australia as previously described (Fong et al., 1995).

The MYCL gene was discovered as two additional DNA fragments of 10.0 kb and 6.6 kb when the MYC gene was used to probe EcoRI digested human genomic DNA (Nau et al., 1985). These fragments represent a RFLP at the MYCL locus, situated in the second intron (Kaye et al., 1988). This RFLP can also be revealed with polymerase chain reaction (PCR) using primers, which flank a 267 bp DNA fragment containing this polymorphism, followed by EcoRI digestion to yield the unique L allele or the cut S allele of 142 and 125 bp (Tamai et al., 1990). DNA from tumour tissue and corresponding normal lung of each patient was examined for this RFLP. Standard PCR conditions were used with restriction enzyme digestion performed according to manufacturer's instructions. PCR products were electrophoretically fractionated in 12% polyacrylamide gels with 10% glycerol and visualised after ethidium bromide staining.

Tumour DNA was also examined for LOH using PCR to amplify a highly polymorphic Alu variable polyA microsatellite marker 16 kb upstream of the MYCL locus (Makela et al., 1992), as previously described (Fong et al., 1995). Statistical analysis included $\chi^2$, t-test and ANOVA (Dawson-Saunders and Trapp, 1990), as well as log-rank analysis of Kaplan–Meier survival curves with a median follow-up duration of 23 months.

Results

The MYCL genotype resulting from an EcoRI RFLP was determined in 108 cases of NSCLC and was identical in the tumour and normal tissue of each patient. There were 30 cases (28%) homozygous for the L allele, 53 (49%) heterozygous for the LS alleles and 25 (23%) homozygous
for the S allele (Figure 1). The L and S allele frequencies were 0.523 and 0.477 respectively, similar to the frequencies reported by Nau et al. (1985), and the genotypes were found to be in accord with Hardy–Weinberg equilibrium \((P=0.987, \chi^2)\).

There was no difference between the genotypes of the two major NSCLC subtypes; squamous cell carcinoma (SCC) and adenocarcinoma. There was also no correlation of the genotypes with either age, sex, smoking history, T, N or TNM stage (Table I).

Furthermore, neither the S allele (LS and SS genotypes) nor homozygosity for the S allele (SS genotype) was associated with T, N or TNM stage (Table II). In addition, there was no difference in the survival of patients with the SS, LS or LL genotypes \([P=0.881, \text{log-rank (data not shown)})\].

Neither was there a survival difference when the S allele (LS and SS genotypes) was compared with the LL genotype \([P=0.856, \text{log-rank (data not shown)})\].

Using a highly polymorphic microsatellite marker just upstream of MYCL (Makela et al., 1992), we found that 85 of our cases were informative for loss of heterozygosity (LOH) analysis, whereas three cases had microsatellite instability and were excluded from LOH analysis (Fong et al., 1995). Twenty-three of these 85 (27%) informative cases showed LOH at the MYCL locus (Figure 2).

**Table II** Tumour stage and various MYCL genotypes

| T stage | LL | LS/SS | P-value \((\chi^2)\) | LL/LS | SS | P-value \((\chi^2)\) |
|---------|----|-------|----------------------|-------|----|----------------------|
| 1       | 7  | 23    | 0.522                | 59    | 19 | 0.630                |
| 2, 3, 4 | 20 | 49    | 0.709                | 56    | 20 | 0.057                |
| N stage | 0  | 20    | 0.005                | 40    | 40 | 0.074                |
| 1, 2    | 10 | 29    | 0.005                | 5     | 5  | 0.522                |
| TNM stage | 1 | 18    | 0.654                | 40    | 7  | 0.074                |
| II, III | 12 | 35    | 0.647                | 40    | 7  | 0.074                |

**Figure 1** Representative examples of the possible MYCL EcoRI RFLP genotypes in paired normal and tumour tissue in individuals with NSCLC. (a) LL homozygote; (b) SS homozygote; (c) LS heterozygote. NL, normal lung; LC, lung cancer. The marker band sizes (bp) are from top to bottom: 387, 458, 437, 323, 289, 267, 241, 171 and 142.

**Figure 2** Representative examples of LOH at the MYCL locus in paired normal and tumour tissue. In each case, normal lung DNA (NL) is in the left lane and lung cancer DNA (LC) is in the right lane, and arrows indicate the deleted alleles.

**Table I** The clinicopathological features of NSCLC patients \((n=108)\) according to MYCL genotype and allelic status (LOH)

| Subtype          | MYCL genotype | SS | P-value \((\chi^2)\) | Informative, no LOH | LOH | P-value \((\chi^2)\) |
|------------------|---------------|----|----------------------|---------------------|-----|----------------------|
| Total number (%) | 30 (28)       | 53 (49) | 25 (23) | 62 (73) | 23 (27) |
| SCC              | 10            | 22   | 11                   | 21                  | 13  | 0.014                |
| Adenocarcinoma   | 16            | 20   | 10                   | 0.490               | 33  | 0.057                |
| Large cell carcinoma | 1           | 2    | 1                    | 1                   | 1   | 0.009                |
| Carcinoid/atypical cancer | 1             | 2    | 1                    | 2                   | 1   | 0.009                |
| Adenosquamous    | 2             | 7    | 2                    | 5                   | 3   | 0.009                |
| Mean age (years) | 61.9          | 61.9 | 58                   | 0.288               | 61  | 0.492                |

**Table I** (continued)

| Subtype          | MYCL genotype | SS | P-value \((\chi^2)\) | Informative, no LOH | LOH | P-value \((\chi^2)\) |
|------------------|---------------|----|----------------------|---------------------|-----|----------------------|
| Sex              | Male          | 22 | 16                   | 43                  | 20  | 0.009                |
|                  | Female        | 8  | 9                    | 19                  | 3   | 0.009                |
| Smoking history  | Never         | 3  | 2                    | 5                   | 1   | 0.009                |
|                  | Past or current | 27 | 23                   | 0.926               | 57  | 0.552                |
|                  | Pack–years smoked | 37.2 | 44.7 | 42.3 | 0.576 | 40.7 | 0.262 | (ANOVA) |
| T stage          | 1             | 7  | 6                    | 20                  | 5   | 0.009                |
|                  | 2, 3, 4       | 23 | 19                   | 0.618               | 42  | 0.344                |
| N stage          | 0             | 20 | 20                   | 46                  | 8   | 0.001                |
|                  | 1             | 10 | 5                    | 0.089               | 16  | 0.001                |
| TNM stage        | I             | 18 | 18                   | 40                  | 7   | 0.001                |
|                  | II, III       | 12 | 7                    | 0.107               | 22  | 0.001                |
Discussion

Our data do not support a role for the S allele of the MYCL gene in determining tumour progression or survival in patients with resected NSCLC in Australia. These data, together with other negative studies in Caucasian and African–American populations (Tamao et al., 1990; Tefre et al., 1990; Weston et al., 1992, 1994), are in direct contrast to the Japanese studies (Kawashima et al., 1988, 1992).

While it is possible that the adverse clinicopathological association of the S allele only applies to Japanese lung cancer patients, studies of other cancers within this population have shown conflicting results, thereby indicating possible tissue specificity. For instance, the S allele was associated with metastases in renal (Kakehi and Yoshida, 1989) and gastric cancers (Ishizaki et al., 1990), but not colorectal or breast cancers (Ikedla et al., 1988; Ishizaki et al., 1990) in Japanese patients. Several studies of cancers other than lung in non-Japanese populations have also linked the S allele with tumour progression. The S allele was associated with tumour size and a lack of differentiation in Indian oral cancer patients (Saranath et al., 1990), and lung metastases in Caucasian breast cancer patients (Champene et al., 1992).

Furthermore, the SS genotype was associated with a worse clinicopathological stage in Australian colorectal cancer patients recruited from the same region in Queensland as our cases (Young et al., 1994).

On the other hand, independent studies have now consistently shown a lack of an adverse impact for the S allele in a variety of Caucasian lung cancer patients, questioning the validity of these observations. While an alternative explanation is that these studies were too insensitive to detect an association, another possibility is that the RFLP within certain populations (ethnic groups) may be in linkage disequilibrium with a gene that is critical to tumour progression and survival. In this regard, it has been demonstrated that the frequency of the EcoR1 RFLP varies by race (Weston et al., 1994). We thus investigated whether LOH, a hallmark feature of tumour-suppressor genes, was present in this chromosomal region.

Although LOH at the 1p32 MYCL locus was not found in Kawashima’s initial study (Kawashima et al., 1988), LOH at 1p has since been described in approximately 15–18% of NSCLCs (Sato et al., 1994; Tsuchiya et al., 1992). Furthermore, new highly polymorphic microsatellite markers have also improved LOH analysis. Using such a marker just upstream of MYCL (Makela et al., 1992), we found that 23 of the 85 (27%) informative cases showed LOH. It should be noted that gene amplification may cause false-positive LOH results by microsatellite analysis (Nagai et al., 1994), this is an unlikely confounder here because MYCL is rarely (<1%) amplified in NSCLC (Bergh, 1990; Shiraishi et al., 1989; Slebos et al., 1989; Yokota et al., 1988). As for clinicopathological features (Table I), the frequency of LOH was significantly higher in SCCs (13/34, 38%) compared with the adenocarcinomas (5/38, 13%; P = 0.014, χ²). Whereas LOH was not associated with age, sex or smoking, it correlated significantly with: (1) hilar and/or mediastinal lymph node involvement (P = 0.001, χ²); and (2) advanced TNM stages (P = 0.005, χ²), indicating that LOH at 1p32 may be a factor in determining tumour progression in NSCLC. There was, however, no survival difference between the NSCLC cases with and without MYCL LOH (P = 0.101, log-rank (data not shown)), which may have been owing to the relatively limited follow-up duration of these surgically treated patients who are known to have the best prognosis of lung cancer sufferers.

This study thus suggests that there may be a tumour-suppressor gene(s) in NSCLC on chromosome 1p, particularly in SCCs, which affects tumour progression. There are similar findings in other cancers; LOH at MYCL correlated with shorter survival after relapse (Biece et al., 1990), while LOH at 1p correlated with nodal metastases (Borg et al., 1992) in breast cancer. LOH at 1p has also been described in other tumours, including neuroblastoma (Weith et al., 1989), melanoma (Dracopoli et al., 1989), Wilms’ tumours (Grundy et al., 1994), phaeochromocytoma (Tsutsuji et al., 1989) and colon cancer (Launten-Puig et al., 1992). More evidence comes from the recent report that allelic loss of 1p was a strong prognostic factor in patients with neuroblastoma, independent of age and stage (Caron et al., 1996). In addition, somatic cell hybrid experiments have shown that the loss of chromosome 1 was associated with the malignant phenotype (Stoler and Bouck, 1985).

As we only investigated LOH at MYCL and did not specifically map the critical region of genetic loss, it is possible that MYCL is not the target gene but may just be deleted coincidentally. For instance, the critical region of loss appears to be distal to MYCL in colorectal cancers (Leister et al., 1990), whereas multiple areas of LOH have been identified in breast cancer, including one just proximal to MYCL (Hoggard et al., 1995). Consequently, candidate genes include pl8 at 1p32 (Guan et al., 1994), as well as other 1p genes such as DAN (Enomoto et al., 1994), RAP1GAI (Weiss et al., 1994) and PITSLRE (Lahti et al., 1994). The increasing availability of closely spaced microsatellite markers should, however, facilitate the localisation and identification of the candidate NSCLC tumour-suppressor gene in the minimally deleted chromosomal region (Gyapay et al., 1994).

Acknowledgements

We are grateful to the medical, nursing and laboratory staff of the Departments of Thoracic Surgery, Thoracic Medicine and Pathology of TPCH and to our patients for participating in this study. We thank Dr J Young, Ms J Kerr, Ms Clay Winterford, Mr J Bruce, Ms Betty Scells, and Mr A Martin for their expert assistance. This study was supported by TPCH, the Queensland Cancer Fund and KF by a NH & MRC (Aust) Medical Postgraduate Scholarship.

References

BERGH JC. (1990). Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes. Acta Oncol., 142, S20–S26.

BIECHE I, CHAMPEME MH, MERLO G, LARSEN CJ, CALLAHAN R AND LIDEREAU R. (1990). Loss of heterozygosity of the L-myc oncogene in human breast tumors. Hum. Genet., 85, 101–105.

BORG A, ZHANG QS, OLSSON H AND WENNGREN E. (1992). Chromosome 1 alterations in breast cancer. Clinical and biological implications. Cancer Genet. Cytogenet., 59, 1–19.

CARON H, VANSULIS P, DEKRAKER J, BOKKERINK J, EGELE M, LAUREYS G, SLATER R, WESTERVELD A, VOUTE PA AND VERSTEEG R. (1996). Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl. J. Med., 334, 225–230.

CHAMPEME MH, BIECHE I, LATIL A, HACENE K AND LIDEREAU R. (1992). Association between restriction fragment length polymorphism of the L-myc gene and lung metastasis in human breast cancer. Int. J. Cancer, 50, 6–9.

CHENEVIX-TRENCH G, SOUTHERN M AND KIDSON C. (1989). Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls. Br. J. Cancer, 60, 872–874.

CROSSEN PE, MORRISON MJ AND COLLS BM. (1994). Increased frequency of the S allele of the L-myc oncogene in non-Hodgkin's lymphoma. Br. J. Cancer, 69, 759–761.

DAWSON-SAUNDERS B AND TRAPP RG. (1990). Basic and Clinical Statistics. pp. 124–141. Appleton & Lange: Norwalk, Conn.
Po-OGAPAY tumour the distal
MATERAG polymorphism in
tion L-myc
tumours.
ISHIZAKI 50,
BATTEY Inst.,
cancer YAMAMOTO,
SALAORNI Genes 1p32.
AND microsatellite
instability and other molecular abnormalities in non-small cell
lung cancer. Cancer Res., 55, 28 – 30.
GRUNDY PE, TELZEROW PE, BRESLOW N, MOKNESS J, HUFF V
AND PATerson MC. (1994). Loss of heterozygosity for
chromosomes 16q and 1p in Wilms' tumours predicts an adverse
outcome. Cancer Res., 54, 2331 – 2333.
GUAN KL, JENKINS CW, LI, NICHOLS MA, WU XY, OKEEFE CL,
MATERA AG AND XIONG Y. (1994). Growth suppression by p18,
a p16(INK4A)- and p14(INK4B)-CDK6 inhibitor, correlates with wild-type pb function. Genes Devel.,
8, 2939 – 2952.
GYAPAY G, MORISSETTE J, VIGNAL A, DIB C, FIZAMES C,
MILLASSEAU P, MARC S, BERNARDI G, LATHROP M AND
WEISSWirth P. (1994). The 1p36.2 region of the human genetic
linkage map. Nature Genet., 7, 246 – 339.
HOGGARD N, BRINTNELL B, HOWELL A, WEISSENBACH J
AND VARLEY J. (1995). Allelic imbalance on chromosome 1 in human breast cancer. II. Microsatellite repeat analysis. Genes Chrom.,
12, 24 – 31.
IKEDA I, ISHIZAKA Y, OCHIAI M, SAKAI R, ITABASHI M, ONDA M,
SUGIMURA T AND NAGAO M. (1988). No correlation between L-
myc restriction fragment length polymorphism and malignancy of
human colorectal cancers. Jpn. J. Cancer Res., 79, 674 – 676.
ISHIZAKA K, KATO M, IKENAGA M, HONDA K, OZAWA K
AND TOUCHUGA J. (1990). Correlation of L-myc genotypes to metastasis of gastric cancer and breast cancer (letter). J. Natl
Cancer Inst., 82, 238 – 239.
KAWASHIMA K AND YOSHIDA O. (1989). Restriction fragment length
polymorphism of the L-myc gene and susceptibility to metastasis in
renal cancer patients. Int. J. Cancer., 43, 391 – 394.
KATO M, TOUCHUGA J, HONDA K, SASAKI MS, IKENAGA M,
SUGIMOTO M, YAMAGUCHI T, KOTOURA Y, YAMAMOTO T,
and ISHIZAKA K. (1990). Elevated frequency of a specific allele of the
L-myc gene in male patients with bone and soft-tissue sarcomas. Int. J. Cancer.,
45, 47 – 49.
KAWASHIMA K, NOMURA S, HIYAI H, FUKUSHI S, KARUBE T,
TAKEUCHI K, NARUKE T AND NISHIMURA S. (1992). Correlation
of L-myc RFLP with metastasis, prognosis and multiple
lung cancer patients. Int. J. Cancer., 50, 557 – 561.
KAWASHIMA K, SHIKAMA H, IMOTO K, IZAWA M, NARUKE T,
OKABAYASHI K AND NISHIMURA S. (1988). Close correlation between
restriction fragment length polymorphism of the L-MYC
gene and metastasis of human lung cancer to the lymph nodes and
other organs. Proc. Natl Acad. Sci. USA., 85, 2353 – 2356.
KAYE F, BATTEY J, NAU M, BROOKS B, SEIFTER E, DE GREVE J,
BIRRER M, SAUVISLE E AND MINNA J. (1988). Structure and
eexpression of the human L-myc gene reveal a complex pattern of
alternative mRNA processing. Mol. Cell. Biol., 8, 186 – 195.
LAHTI JM, VAILENTINE M, XIANG J, JONES B, AMANN J, GRENET J,
RICHMOND G, LOOK AT AND KIDD VI. (1994). Alterations in
the PITSRL protein kinase gene complex on chromosome 1p36 in
childhood neuroblastoma. Nature Genet., 7, 370 – 375.
LAURENT-PUIG P, OLSCHWANG S, DELATTRE O, REMVIKOS Y,
ASSELIN B, MELOT T, VALIDIRE P, MULERIS M, GIRODET J,
SALMON R, THOMAS G AND GRODIN (1992). Survival and acquired
genetic alterations in colorectal cancer. Gastroenterology, 102,
1136 – 1141.
LEISTER I, WEITH A, BRUDERLEIN S, CIZEPLUCH C, KANGWAN-
PONG D, SCHLAG P AND SCHWAB M. (1990). Human colorectal
cancer: high frequency of deletions at chromosome 1p35. Cancer
Res., 50, 2723 – 2735.
MAKEI TP, HELLSTEN E, VESA J, ALITALO K AND PELTONEN L.
(1992). An Alu variable polyA repeat polymorphism upstream of
L-myc at 1p32. Hum. Mol. Genet., 1, 217.
NAU MA, YAMAMOTO I, SALORNI S, PACHECO MM, BRENATA-
NI MM, BARBOSA EM, BRENATANI RR, MAZOWER S, SMITH SA,
PONDER B AND MULLIGAN LM. (1994). Detailed deletion
mapping of chromosome segment 17q12 – 21 in sporadic breast
neoplasms. Genes Chrom. Cancer, 11, 58 – 62.